'One-visit' therapy for pelvic inflammatory disease.
Acute pelvic inflammatory disease is a very common gynaecological disorder, and more often than not it is caused by a mixed infection of aerobic and anaerobic organisms. Routine bacteriological investigation is consequently of little practical value in determining the therapeutic approach. In an open comparative trial, 60 patients were divided into two treatment groups of 30 patients each. Both groups received a combination of penicillins, probenecid, a sulphonamide and an imidazole derivative active against protozoa and anaerobes. Both regimens resulted in virtually the same therapeutic response in patients hospitalized for 6 days. The regimen consisting of ornidazole (as opposed to metronidazole) and the ultralong-acting sulphonamide, sulphadoxine (as opposed to sulphadimidine), can be given in a once-only administration, thereby greatly reducing the possibility of non-compliance in patients treated, as is customary, on an outpatient basis.
D000208:Acute Disease; D001799:Blood Sedimentation; D004359:Drug Therapy, Combination; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D005334:Fever; D006801:Humans; D007958:Leukocyte Count; D007973:Leukorrhea / Q000188:drug therapy; D008795:Metronidazole / Q000627:therapeutic use*; D009593:Nitroimidazoles / Q000627:therapeutic use*; D009950:Ornidazole / Q000627:therapeutic use*; D010349:Patient Compliance; D011339:Probenecid / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000627:therapeutic use*; D013418:Sulfamethazine / Q000627:therapeutic use*; D013424:Sulfanilamides / Q000627:therapeutic use*; D013997:Time Factors; D014627:Vaginitis / Q000188:drug therapy* / Q000382:microbiology
D009593:Nitroimidazoles; D013424:Sulfanilamides; D008795:Metronidazole; D013418:Sulfamethazine; D009950:Ornidazole; D013413:Sulfadoxine; D011339:Probenecid